Neurocrine Bio. (NBIX) PT Lowered to $173 at Morgan Stanley
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $152.72 +1.26%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $173.00 (from $178.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley
- Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins
- Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
